Evidence map›Paper›PMID 39376170›Full record

ReviewTechnology in cancer research & treatment

Gastric Cancer Signaling Pathways and Therapeutic Applications.

Mingfang Wu, Shiman Yuan, Kai Liu, Chenyu Wang, Feng Wen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Biological Activity of Peptide Fraction Derived fromInternational journal of molecular sciences · 2025
    Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mingfang WuThe Second Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, Guiyang, China.
Shiman YuanThe Clinical Medical College, Guizhou Medical University, Guiyang, China.
Kai LiuThe Clinical Medical College, Guizhou Medical University, Guiyang, China.
Chenyu WangThe Second Clinical Medical College, Lanzhou University, Lanzhou, China.
Feng WenDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Sichuan, China.ORCID 0009-0009-6203-0559

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer (GC) is a prevalent malignant tumor and ranks as the second leading cause of death among cancer patients worldwide. Due to its hidden nature and difficulty in detection, GC has a high incidence and poor prognosis. Traditional treatment methods such as systemic chemotherapy, radiotherapy, and surgical resection are commonly used, but they often fail to achieve satisfactory curative effects, resulting in a very low 5-year survival rate for GC patients. Currently, targeted therapy and immunotherapy are prominent areas of research both domestically and internationally. These methods hold promise for the treatment of GC. This article focuses on the signaling pathways associated with the development of GC, as well as the recent advancements and applications of targeted therapy and immunotherapy. The aim is to provide fresh insights for the clinical treatment of GC.

Indexed as

ImmunotherapyMolecular Targeted TherapySignal TransductionStomach NeoplasmsAnimalsBiomarkers, TumorDisease ManagementHumansBiomarkers, Tumorgastric cancerimmune checkpoint inhibitorsimmunotherapysignaling pathwaytargeted therapy

Identifiers

PMID39376170
PMCPMC11468335

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.